Skip to content

Assessment of Pharmacokinetic Interactions and Therapeutic Effect of Chandraprabha vati with Glimepiride

Assessment of Metabolism mediated Pharmacokinetic Interactions and Therapeutic Potential of Chandraprabha vati with Glimepiride - Nil

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065273
Enrollment
24
Registered
2024-04-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

SRM College of Pharmacy SRM Institute of Science and Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Willing to give informed written consent and comply with the study requirements 2 Subject should be able to communicate effectively 3 Non smokers or individuals who smoke less than 5 cigarettes per day 4 Teetotalers or individuals who drink less than 60 ml of high alcohol content liquor or 120 ml of low-alcohol content liquor 5 Body Mass Index between 19 to 25 6 Healthy individuals as evaluated by personal history medical history and general clinical examination 7 BP should be within the range of 100 to 139 systolic and 60 to 89 diastolic Pulse rate should be within the range of 60 to 100 beats per minute Temperature between 97.8 and 99.0 degree Respiratory rate should be within the range of 14 to 18 breaths per minute 8 Normal biochemical hematological and urinary parameters 9 Normal Chest X ray 10 Negative for sexually transmitted diseases Hepatitis B Hepatitis C and Syphilis tests 11 Negative urine test for drugs of abuse for morphine barbiturates benzodiazepines amphetamine cocaine to be performed on the day of check in 12 Negative alcohol breathe analysis to be performed on the day of check in

Exclusion criteria

Exclusion criteria: 1 Subjects incapable of understanding the informed consent 2 History of any major surgical procedure in the past 3 months 3 History of diabetes mellitus tuberculosis and systemic hypertension 4 History suggestive of cardiac gastrointestinal respiratory hepatic renal endocrine neurological metabolic psychiatric or haematological systems judged to be clinically significant 5 History of dysphagia 6 History of any medical disorder that is of significance in the investigators opinion 7 Present or past history of drug abuse 8 History of hypersensitivity to study formulation 9 History of allergy to vegetables and or food substances and or any other manifestations suggestive of hypersensitivity reactions 10 Present or past history of intake of drugs which potentially modify kinetics or dynamics of study medication or any other medication judged to be clinically significant by the investigator 11 Consumption of grapefruit or its products within 48 hours prior to the start of the study

Design outcomes

Primary

MeasureTime frame
1 To determine the effect of multiple oral doses of Chandraprabha vati on the single dose Glimepiride administered in healthy adult volunteers 2 Area under the curve 3 Total body clearance 4 Volume of distribution at steady state 5 Terminal half life 6 Extent of absolute oral bioavailability 7 Peak plasma concentration 8 Time taken to reach Peak plasma concentration Timepoint: Baseline Third Month Sixth Month

Secondary

MeasureTime frame
to measure adverse drug reactions during the study periodTimepoint: Baseline Third Month Sixth Month

Countries

India

Contacts

Public ContactDr T M Vijayakumar

SRM College of Pharmacy,SRMIST

vijayakm2@srmist.edu.in9003400350

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026